Industry veteran Abbas Hussain named chairman of Asceneuron

18 December 2023
boardroom_big

Switzerland-based Asceneuron has announced the appointment of Abbas Hussain as its new chairman of to its board of directors.

Privately-held Asceneuron was created n 2012 as a spin-out of Merck KGaA’s (MRK: DE) Merck Serono division, with the aim of developing therapies for the treatment of Alzheimer's disease and Tau protein-related pathologies, by advancing Merck Serono's pre-clinical programs targeting these conditions towards clinical testing as rapidly as possible.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >






Company Spotlight



More Features in Biotechnology